Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage

William L Henrich, D. C. Brater, W. B. Campbell

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Original languageEnglish
Pages (from-to)484-489
Number of pages6
JournalKidney International
Volume29
Issue number2
StatePublished - 1986
Externally publishedYes

Fingerprint

Therapeutic Uses
Hemodynamics
Hemorrhage
Kidney
Glomerular Filtration Rate
Renal Circulation
Dogs
Prostaglandins
Urine
sulindac sulfide
Indomethacin
Pharmaceutical Preparations
Arterial Pressure
Anti-Inflammatory Agents
Control Groups
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage. / Henrich, William L; Brater, D. C.; Campbell, W. B.

In: Kidney International, Vol. 29, No. 2, 1986, p. 484-489.

Research output: Contribution to journalArticle

@article{b8b4c2ff99054d92b7c4af8e3c42983f,
title = "Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage",
abstract = "There is continued debate over any renal-sparing effects of sulindac (S): such a property would be of benefit and be unique among nonsteroidal anti-inflammatory drugs (NSAIDS). S undergoes a distinct metabolism whereby the active drug (sulindac sulfide (SS) does not appear in the urine. Accordingly, we tested the effect of a plasma concentration of SS in the therapeutic range on renal blood flow (RBF), glomerular filtration rate (GFR) and renal prostaglandin (PG) concentrations during sudden renal ischemic stress. The ischemic stress was produced by a 15 to 20{\%} reduction in arterial pressure by arterial hemorrhage (H) in four separate groups of anesthetized dogs: control, SS (0.4 mg/kg i.v. bolus followed by 0.03 mg/kg/min constant infusion), indomethacin (I, 10 mg/kg), and benoxaprofen (B, 75 mg/kg). A plasma concentration of 3.69 μg/ml of SS was achieved by the infusion, and no SS appeared in the urine. H reduced GFR (by 46{\%}) and RBF (by 38{\%}) in control dogs; in SS-treated dogs, a 60{\%} decline in GFR and a 73{\%} decrease in RGF occurred. These decreases in renal hemodynamics in the SS group during H were significantly greater than in the control group. Further, these decrements in GFR and RBF were similar to those observed in the I- and B-treated dogs. Finally, SS reduced baseline arterial and renal PG concentrations, and prevented any increase in renal PG release during H. Thus, we conclude that a concentration of SS in the therapeutic range, which does not appear in the urine, is capable of enhancing the decline in GFR and RBF during a sudden ischemic stress such as H.",
author = "Henrich, {William L} and Brater, {D. C.} and Campbell, {W. B.}",
year = "1986",
language = "English",
volume = "29",
pages = "484--489",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Renal hemodynamic effects of therapeutic plasma levels of sulindac sulfide during hemorrhage

AU - Henrich, William L

AU - Brater, D. C.

AU - Campbell, W. B.

PY - 1986

Y1 - 1986

N2 - There is continued debate over any renal-sparing effects of sulindac (S): such a property would be of benefit and be unique among nonsteroidal anti-inflammatory drugs (NSAIDS). S undergoes a distinct metabolism whereby the active drug (sulindac sulfide (SS) does not appear in the urine. Accordingly, we tested the effect of a plasma concentration of SS in the therapeutic range on renal blood flow (RBF), glomerular filtration rate (GFR) and renal prostaglandin (PG) concentrations during sudden renal ischemic stress. The ischemic stress was produced by a 15 to 20% reduction in arterial pressure by arterial hemorrhage (H) in four separate groups of anesthetized dogs: control, SS (0.4 mg/kg i.v. bolus followed by 0.03 mg/kg/min constant infusion), indomethacin (I, 10 mg/kg), and benoxaprofen (B, 75 mg/kg). A plasma concentration of 3.69 μg/ml of SS was achieved by the infusion, and no SS appeared in the urine. H reduced GFR (by 46%) and RBF (by 38%) in control dogs; in SS-treated dogs, a 60% decline in GFR and a 73% decrease in RGF occurred. These decreases in renal hemodynamics in the SS group during H were significantly greater than in the control group. Further, these decrements in GFR and RBF were similar to those observed in the I- and B-treated dogs. Finally, SS reduced baseline arterial and renal PG concentrations, and prevented any increase in renal PG release during H. Thus, we conclude that a concentration of SS in the therapeutic range, which does not appear in the urine, is capable of enhancing the decline in GFR and RBF during a sudden ischemic stress such as H.

AB - There is continued debate over any renal-sparing effects of sulindac (S): such a property would be of benefit and be unique among nonsteroidal anti-inflammatory drugs (NSAIDS). S undergoes a distinct metabolism whereby the active drug (sulindac sulfide (SS) does not appear in the urine. Accordingly, we tested the effect of a plasma concentration of SS in the therapeutic range on renal blood flow (RBF), glomerular filtration rate (GFR) and renal prostaglandin (PG) concentrations during sudden renal ischemic stress. The ischemic stress was produced by a 15 to 20% reduction in arterial pressure by arterial hemorrhage (H) in four separate groups of anesthetized dogs: control, SS (0.4 mg/kg i.v. bolus followed by 0.03 mg/kg/min constant infusion), indomethacin (I, 10 mg/kg), and benoxaprofen (B, 75 mg/kg). A plasma concentration of 3.69 μg/ml of SS was achieved by the infusion, and no SS appeared in the urine. H reduced GFR (by 46%) and RBF (by 38%) in control dogs; in SS-treated dogs, a 60% decline in GFR and a 73% decrease in RGF occurred. These decreases in renal hemodynamics in the SS group during H were significantly greater than in the control group. Further, these decrements in GFR and RBF were similar to those observed in the I- and B-treated dogs. Finally, SS reduced baseline arterial and renal PG concentrations, and prevented any increase in renal PG release during H. Thus, we conclude that a concentration of SS in the therapeutic range, which does not appear in the urine, is capable of enhancing the decline in GFR and RBF during a sudden ischemic stress such as H.

UR - http://www.scopus.com/inward/record.url?scp=0022601932&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022601932&partnerID=8YFLogxK

M3 - Article

C2 - 3754595

AN - SCOPUS:0022601932

VL - 29

SP - 484

EP - 489

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -